Schering Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Drug Discovery, Inc.

Other

Southern Research Institute

Pharmacopeia Inc.

Seong Heon Kim

Joseph A Kozlowski

Wensheng Yu

Bandarpalle B Shankar

Michael K C Wong

Ling Tong

De-Yi Yang

Neng-Yang Shih

Brian J Lavey

Guowei Zhou

Lei Chen

Dansu Li

Vinay M Girijavallabhan

Kristin E Rosner

Stuart B Rosenblum

M Arshad Siddiqui

Janeta Popovici-Muller

Razia Rizvi

Chaoyang Dai

Vincent Stewart Madison

Zhuyan Guo

Brian F McGuinness

Peter Orth

Douglas Walsh Hobbs

Qingbei Zeng

Umar Faruk Mansoor

John J Baldwin

F George Njoroge

Frank W Bennett

Ashok Arasappan

Srikanth Venkatraman

John A Secrist, Iii

Malcolm Maccoss

Subramaniam Ananthan

Kartik M Keertikar

Francisco Velazquez

Joseph A Maddry

Vishal Verma

Feng Geng

Gopinadhan N Anilkumar

Robert Feltz

Yuefei Shao

Judson E Richard

Luke Fire

Aneta Maria Kosinski

Lisa Guise Zawacki

Guizhen Dong

Liping Yang

Aneta M Micula

Anilkumar G Nair

Paul J Zavodny

Yuhua Huang

Robert C Reynolds

Oleg B Selyutin

Chung-Her Jenh

Hollis S Kezar, Iii

Anita T Fowler

Cecil D Kwong

Yueheng Jiang

Abhijit Roychowdhury

Kristen E Rosner

Carolyn Dilanni Carroll

Cangmeng Yang

Michael Wong

Aneta Maria Kosinzki

Doublas W Hobbs

Razia K Rizvi

Michael KC Wong

John A Iii Secrist

Kerry M Keertikar

Anilkumar Gopinadhan Nair

Hollis S Iii Kezar

George F Njoroge

Brian F Mc Guinness

Changmeng Yang

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M, Xand Xare as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.

Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Heterocyclic substituted piperazines with CXCR3 antagonist activity

This invention relates to compounds of the Formula (I): 

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Substituted heterocyclic compounds with CXCR3 antagonist activity

Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

Piperazine-piperidines with CXCR3 antagonist activity

Growing community of inventors

Livingston, NJ, United States of America

Seong Heon Kim